New CEO Jake Leach said the company plans a trial readout in mid-2026 to support coverage of its glucose sensors in Type 2 users who don’t take insulin.
March 24--Shares of DexCom gained more than 8 percent Friday after Medicare issued a favorable ruling for reimbursing use of continuous glucose monitors, made by the San Diego-based company. DexCom ...
DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced a significant advancement in access to its products for those treating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results